

## Air Liquide is awarded a large contract in Spain to care for patients living with respiratory conditions at home

The Community of Madrid, Spain, has selected Air Liquide to support at home 70,000 patients living with respiratory conditions. In Spain, the autonomous regional governments are responsible for organising healthcare resources in their respective regions, and therefore also for designing and implementing the outsourcing of these resources. This five-year contract follows a public tender process, during which Air Liquide's proposal stood out for the operational excellence and the effectiveness of its digital and AI solutions, which are designed to improve patient health outcomes and their quality of life in their homes, by optimizing the care pathway at the lowest cost to society. It also consolidates Air Liquide's leadership position in the Spanish market.

With this contract, Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea. According to the WHO and the European Respiratory Society (ERS), COPD cases are projected to increase by 23% globally by 2050<sup>1</sup>. The healthcare services provided at home enable chronic patients to meet their needs and maintain their autonomy and quality of life.

The contract was awarded based on a **comprehensive, personalized support proposal** tailored to patient profiles, with special monitoring for highly dependent individuals. From hospital discharge to home, Air Liquide's approach includes several ways, at the patient's choice, to interact with (in-person visits, video consultations, digital tools) and also telemonitoring, educational and psychological support, to provide continuous support and facilitate the early detection of compliance issues and real-time treatment adaptation. An App, already used by 100,000 patients, is part of the approach and a platform, which collects data and measures health outcomes, is integrated into the healthcare professionals' portal. This shared access, coupled with proactive monitoring, aims to **improve patients' health outcomes and reduce hospital admissions' risks, thereby helping to contain healthcare costs.**

Patients and healthcare professionals can rely on the **expertise of an experienced and highly qualified multidisciplinary team of the Air Liquide**, including nurses, physiotherapists, pulmonologists, clinical psychologists, speech therapists, and nutritionists. Ongoing training and biannual skills assessments complement their specific training in home respiratory therapies.

**Diana Schillag**, member of Air Liquide's Executive Committee, overseeing Healthcare, stated: **"This new contract with the Community of Madrid, in Spain, illustrates our ability to innovate and deliver quality healthcare services tailored to the needs of patients at home. In addition to the human support of our teams, the integration of advanced technologies, such as predictive algorithms, cost-effectiveness assessments of telemonitoring, and the use of artificial intelligence demonstrate an innovative approach aimed at improving patients' quality of life and generating a positive impact on the healthcare system."**

### About Air Liquide Healthcare

Air Liquide Healthcare is a world leader in medical gases, home healthcare services and specialty ingredients. Our 15,600 employees support 2.1 million chronic patients and provide medical gases and related services to 20,000 hospitals and new care facilities, as well as to 140,000 healthcare professionals. Committed to working alongside professionals and health institutions, our patient-centered approach is based on the principles of Value-based Healthcare, which aims to improve the benefits experienced by patients, at the best cost for society, thus contributing to a more efficient and virtuous system.

In Spain, Air Liquide accompanies more than 600,000 patients with a growing presence over the last 30 years.

<sup>1</sup> Chronic respiratory diseases and health equity by 2050 a spotlight on chronic obstructive pulmonary disease and asthma in the WHO European Region, June 2025

## CONTACTS

**Corporate Communications**  
media@airliquide.com

**Investor Relations**  
IRTeam@airliquide.com

---

Air Liquide is a world leader in gases, technologies and services for industry and healthcare. Present in 60 countries with approximately 66,500 employees, the Group serves more than 4 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide's scientific territory and have been at the core of the Group's activities since its creation in 1902.

Taking action today while preparing the future is at the heart of Air Liquide's strategy. With ADVANCE, its strategic plan, Air Liquide is targeting a global performance, combining financial and extra-financial dimensions. Positioned on new markets, the Group benefits from major assets such as its business model combining resilience and strength, its ability to innovate and its technological expertise. The Group develops solutions contributing to climate and the energy transition — particularly with hydrogen — and takes action to progress in areas of healthcare, electronics and high technologies.

Air Liquide's revenue amounted to more than 27 billion euros in 2024. Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, CAC 40 ESG, EURO STOXX 50, FTSE4Good and DJSI Europe indexes.